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protein expression. Recently, mRNA-based therapy has blossomed into
a potential therapeutic agent to prevent and treat a broad range of dis-
eases. This is fundamentally a newwayof treating rare inherited genetic
diseases with signiﬁcant pediatric morbidity and mortality. mRNA re-
placement therapy is also a potential alternative to treat diseases that
are incompatible with protein replacement therapies [1]. Delivering
mRNA rather than proteins could potentially help eliminate the costly
and lengthy steps for protein development and manufacture. Exoge-
nously delivered mRNA only has to cross the plasma membrane and
does not alter the host genome and therefore does not have the safety
concerns associated with genome editing.
This rapidly growing ﬁeld has spawned numerous commercial en-
deavors with several potential therapies currently being evaluated in
Phases II and III clinical trials. These efforts have mainly been focused
on mRNA-based cancer immunotherapies and cancer vaccines, while
treatments for rare genetic diseases are still either in the preclinical
stage or just starting Phase I trials [2,3]. Nevertheless, extensive preclin-
ical evaluation of mRNA therapy especially with respect to their long-
term efﬁcacy, safety and tolerability remains a critical knowledge gap
towards clinical translation. In this article of EBioMedicine, Ding An
and colleagues completed a comprehensive preclinical evaluation of
mRNA therapy in treating methylmalonic acidemia (MMA), and
showed this therapy has sustained functional beneﬁt and is well toler-
ated systemically [4].
A main delivery vehicle for mRNA is a synthetic lipid nanoparticle
(LNP). Typically, multiple mRNA molecules are sterically caged within
a sub 100 nm biodegradable, ionizable lipid membrane. When system-
ically injected, these complex molecules are intrinsically targeted to the
liver in vivo. MMA is a rare genetic disease that can lead to liver andDOI of original article: https://doi.org/10.1016/j.ebiom.2019.07.003.
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pre-clinical efﬁcacy and toxicity of mRNA therapeutics.
MMA occurs in ~1:100,000 live births and is caused by deleterious
mutations of the human methylmalonyl-coenzyme A (CoA) mutase
gene (hMUT) that leads to a toxic accumulation of methylmalonic acid
in the blood [5]. The ideal treatment is to supplement the patient with
fully functional hMUT enzyme. An et al. [4] extended their previous
work [6] in murine models of MMA by expanding the treatment period
from 2-weeks to 12-weeks. They evaluated a severemodel that only ex-
presses hMUT in muscle-tissue to rescue neonatal lethality (Mut−/−;
TgINS-MCK-Mut) and a hypomorphic model that systemically express a
hMut variantwith reduced enzymatic activity (Mut−/−;TgINS-CBA-G715V).
An et al [4] ﬁrst studied the dose-response of the mRNA therapeutic
in vivo. Plasma levels of methylmalonic acid decreased substantially
over two weeks before reverting to baseline. For the long-term study
bi-monthly injections of 0.5 and 2 mg/kg of hMUT mRNA formulated
in LNPs showed a sustained statistically-signiﬁcant increase in serum
hMUT protein and decrease in plasma levels of methylmalonic acid
over the 12-week study (with 11–12 mice per group). Tolerability of
themRNA therapeutic was evaluated through frequent clinical observa-
tions and toxicity was evaluated both with clinical chemistry as well as
liver enzyme levels. The Kaplan-Meier survival curves for the severe
murine model showed a dramatic difference between the therapeutic
over the PBS control group. The mRNA therapeutic also improved in
clinical outcomes and clinical chemistry for the hypomorphic model.
The therapeutic waswell tolerated in bothmodels and showedminimal
toxicity with minimal damage to extrahepatic tissues.
In their mRNA designs, uridines were replaced with 5-
methodxyuridine to limit the immunological response. These modiﬁed
bases are not well recognized by the immune system and limit its acti-
vation [7]. In vivo, the LNP is thought to be uptaken by the hepatocytes
through the endocytosis. hMUT mRNA is translated in the cytoplasm
and functional hMUT protein is then trafﬁcked to mitochondria [6].
LNPs containing this hMUT mRNA were assembled using a cartridge
basedmicroﬂuidic systems [8], and they are composed of a complex for-
mulation of ionizable lipid, phosphocholine, cholesterol andthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
24 J. Zimak et al. / EBioMedicine 46 (2019) 23–24polyethylene glycol (PEG). The wide-scale manufacturability of these
complexes needs to be addressed in the future. The biodistribution of
LNPs favors the liver and spleen they are rapidly cleared from the
blood and not detectable in the kidney, heart, lung and lymph node [9].
The sustained bioactivity and pharmacology of mRNA therapy ob-
served in this study paves the way for a clinical evaluation. While the
translational potential of this work is clear, there remain feasibility
gaps in both product development and clinical development that need
to be answered in the long term.What percent ofmRNA-LNPs are deliv-
ered to cells? Can the economics of manufacturing mRNA-LNP and
treating thousands of patients scale? If so, will patients be required
and willing to receive injections every two weeks for the rest of their
lives? The initial promise ofmRNA-based therapeutics lay in cancer vac-
cines and the delivery of cancer immunotherapies that require small
numbers of doses, so it remains to be seen whether it can be a long-
term palliative therapy. For other diseases, the delivery of mRNA and
tropism of LNPs to extrahepatic tissue needs to be addressed [3]. Strat-
egies such as rationally-designed targeting approaches including cou-
pling tissue-speciﬁc ligands to the LNPs could be evaluated [10]. In
addition, synthetic UTR elements and N1-methyl pseudouridine can
be explored to prolong and increase expression, respectively. In conclu-
sion, An et al demonstrated that LNP-deliveredmRNA therapy for MMA
may be a viable candidate for clinical trials.
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